EUVIMEDEUVIMED entdecken
Open Access

Long-term clinical outcomes of intravascular brachytherapy for multilayer drug-eluting in-stent restenosis

Richard Tanner, Vishal Dhulipala, Udit Joshi, Manish Vinayak, Serdar Farhan, Pier Pasquale Leone, Samantha Sartori, Kenneth Smith, Michael Buckstein, Amit Hooda, Raman Sharma, Joseph M Sweeny und 3 weitere

EuroIntervention · 2025

DOI: 10.4244/eij-d-24-00807 ↗

Kurz gefasst

Fachartikel in der Zeitschrift EuroIntervention, 2025. Verfasst von Richard Tanner und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Fuster Heart Hospital, New York, NY, USA. Hauptthemen laut MEDLINE: Drug-Eluting Stents, Brachytherapy, Coronary Restenosis, Percutaneous Coronary Intervention. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Multilayer in-stent restenosis (ISR) remains a clinical challenge. Intravascular brachytherapy (IVBT) offers a "metal-free" treatment modality for multilayer drug-eluting stent (DES)-ISR; however, long-term outcome data on IVBT safety and efficacy are lacking. AIMS: We sought to compare 3-year clinical outcomes between patients treated with IVBT and those treated with a non-IVBT strategy. METHODS: Patients treated for multilayer DES-ISR (≥2 layers) at Mount Sinai Hospital (2012-2019) were included for analysis. The primary outcome was major adverse cardiac events (MACE), a composite of all-cause death, target lesion revascularisation and myocardial infarction, at 3-year follow-up. RESULTS: A total of 647 patients (mean age 66.6±9.9 years, 25.5% female) were included: 453 patients (70%) were treated with IVBT and 194 patients (30%) with a non-IVBT strategy. Baseline characteristics were similar, except for IVBT-treated patients having a higher incidence of prior coronary artery bypass grafting. The IVBT group had a lower mean SYNTAX score (11.9±10.7 vs 14.2±11.3; p=0.028) and were significantly less likely to receive a DES (0.4% vs 25.8%; p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug-Eluting StentsBrachytherapyCoronary RestenosisPercutaneous Coronary InterventionHumansFemaleAgedMaleTreatment OutcomeMiddle AgedRetrospective StudiesTime Factors

Autor:innen und Institutionen

  • Department of Cardiology, The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Fuster Heart Hospital, New York, NY, USA.
  • Department of Cardiology, Mater Private Network, Cork, Ireland.
  • Department of Radiation Oncology, Mount Sinai, New York, NY, USA.

Zitieren

APA

Tanner, R., Dhulipala, V., Joshi, U., Vinayak, M., Farhan, S., Leone, P. P., Sartori, S., Smith, K., Buckstein, M., Hooda, A., Sharma, R., Sweeny, J. M., Mehran, R., Kini, A. S., & Sharma, S. K. (2025). Long-term clinical outcomes of intravascular brachytherapy for multilayer drug-eluting in-stent restenosis. EuroIntervention. https://doi.org/10.4244/eij-d-24-00807

Vancouver

Tanner R, Dhulipala V, Joshi U, Vinayak M, Farhan S, Leone PP, et al. Long-term clinical outcomes of intravascular brachytherapy for multilayer drug-eluting in-stent restenosis. EuroIntervention. 2025. doi:10.4244/eij-d-24-00807

BibTeX
@article{Tanner2025,
  author = {Tanner, Richard and Dhulipala, Vishal and Joshi, Udit and Vinayak, Manish and Farhan, Serdar and Leone, Pier Pasquale and Sartori, Samantha and Smith, Kenneth and Buckstein, Michael and Hooda, Amit and Sharma, Raman and Sweeny, Joseph M and Mehran, Roxana and Kini, Annapoorna S and Sharma, Samin K},
  title = {Long-term clinical outcomes of intravascular brachytherapy for multilayer drug-eluting in-stent restenosis},
  journal = {EuroIntervention},
  year = {2025},
  doi = {10.4244/eij-d-24-00807}
}
Kostenlos starten →